Skip navigation

Innovative Contracting and Pricing Strategies in an Ultra-Competitive and Evolving Healthcare System

January 23-24, 2019
  • Philadelphia, PA
INDUSTRY UPDATE: Market access is being repositioned as a function fit for purpose in a new era of costly cures, where value-based drug evaluation frameworks are building roots and becoming institutionalized. In our Value-Based Model Intensive, gain the details on value-based contracting for digital therapeutics and key takeaways on HEOR around the world! We will also be touching on 340B changes such as HRSA accelerating implementation of the long-delayed 340B pricing and manufacturer penalties rule and the guidance updates issued by HRSA that suggest tightening of 340B covered entity repayment rules in our 340B-focused sessions featuring perspectives from Boone County Hospital, ProMedica and more. Other industry updates that we look forward to discussing in January are Express Scripts’ Flex Formulary and the Trump administration’s draft proposed rule titled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Costs”.

Now in its sixth year, CBI’s Reimbursement and Contracting provides a platform for bio/pharmaceutical manufacturers looking to unravel complexities associated with reimbursement, pricing strategies and commercial contracting. As pricing pressures and competition continue to mount, reimbursement, pricing and contract teams must navigate evolving landscapes to developing competitive pricing strategies. Join experts to discuss the latest on patient access, reform, ACOs, IDNs, health insurance exchanges, Medicare Part D, 340B and much more!

Key Insights and Takeaways:

  • Navigate the latest healthcare updates and implications
    for contracting and reimbursement
  • Align new technologies and treatment paradigms and
    AI technologies
  • Uncover leading contracting and pricing strategies for
    optimized reimbursement
  • Overcome key challenges for specialty products and biosimilars
  • Shine light on value-based contracting from a payers perspective
  • Benefit from an in-depth case study on outcomes-based
    contracting — What happens after the signature?

HEAR FROM PAST ATTENDEES:

Excellent conference to bring
the commercial and government contracting
perspectives together.

Department Director, Government Contracts & Reporting, Bayer

Extremely well run conference where
ideas were shared so everyone could benefit
and learn from the group!

Business Relations Manager, Sanofi Genzyme

The in-depth introduction of pros and cons for
outcomes-based contracting opened the
door for exploration
.

Senior Business Partner, Indivior

6th Annual Reimbursement and Contracting

Innovative Contracting and Pricing Strategies in an Ultra-Competitive and Evolving Healthcare System

INDUSTRY UPDATE: Market access is being repositioned as a function fit for purpose in a new era of costly cures, where value-based drug evaluation frameworks are building roots and becoming institutionalized. In our Value-Based Model Intensive, gain the details on value-based contracting for digital therapeutics and key takeaways on HEOR around the world! We will also be touching on 340B changes such as HRSA accelerating implementation of the long-delayed 340B pricing and manufacturer penalties rule and the guidance updates issued by HRSA that suggest tightening of 340B covered entity repayment rules in our 340B-focused sessions featuring perspectives from Boone County Hospital, ProMedica and more. Other industry updates that we look forward to discussing in January are Express Scripts’ Flex Formulary and the Trump administration’s draft proposed rule titled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Costs”.

Now in its sixth year, CBI’s Reimbursement and Contracting provides a platform for bio/pharmaceutical manufacturers looking to unravel complexities associated with reimbursement, pricing strategies and commercial contracting. As pricing pressures and competition continue to mount, reimbursement, pricing and contract teams must navigate evolving landscapes to developing competitive pricing strategies. Join experts to discuss the latest on patient access, reform, ACOs, IDNs, health insurance exchanges, Medicare Part D, 340B and much more!

Key Insights and Takeaways:

  • Navigate the latest healthcare updates and implications
    for contracting and reimbursement
  • Align new technologies and treatment paradigms and
    AI technologies
  • Uncover leading contracting and pricing strategies for
    optimized reimbursement
  • Overcome key challenges for specialty products and biosimilars
  • Shine light on value-based contracting from a payers perspective
  • Benefit from an in-depth case study on outcomes-based
    contracting — What happens after the signature?

HEAR FROM PAST ATTENDEES:

Excellent conference to bring
the commercial and government contracting
perspectives together.

Department Director, Government Contracts & Reporting, Bayer

Extremely well run conference where
ideas were shared so everyone could benefit
and learn from the group!

Business Relations Manager, Sanofi Genzyme

The in-depth introduction of pros and cons for
outcomes-based contracting opened the
door for exploration
.

Senior Business Partner, Indivior